Preclinical Cognitive Markers of Alzheimer Disease and Early Diagnosis Using Virtual Reality and Artificial Intelligence: Literature Review

Preclinical Cognitive Markers of Alzheimer Disease and Early Diagnosis Using Virtual Reality and Artificial Intelligence: Literature Review

Abstract BackgroundThis review explores the potential of virtual reality (VR) and artificial intelligence (AI) to identify preclinical cognitive markers of Alzheimer disease (AD). By synthesizing recent studies, it aims to advance early diagnostic methods to detect AD before s...

Full description

Saved in:
Bibliographic Details
Main Authors: María de la Paz Scribano Parada, Fátima González Palau, Sonia Valladares Rodríguez, Mariano Rincon, Maria José Rico Barroeta, Marta García Rodriguez, Yolanda Bueno Aguado, Ana Herrero Blanco, Estela Díaz-López, Margarita Bachiller Mayoral, Raquel Losada Durán
Format: Article
Language:English
Published: JMIR Publications 2025-01-01
Series:JMIR Medical Informatics
Online Access:https://medinform.jmir.org/2025/1/e62914
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract BackgroundThis review explores the potential of virtual reality (VR) and artificial intelligence (AI) to identify preclinical cognitive markers of Alzheimer disease (AD). By synthesizing recent studies, it aims to advance early diagnostic methods to detect AD before significant symptoms occur. ObjectiveResearch emphasizes the significance of early detection in AD during the preclinical phase, which does not involve cognitive impairment but nevertheless requires reliable biomarkers. Current biomarkers face challenges, prompting the exploration of cognitive behavior indicators beyond episodic memory. MethodsUsing PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched Scopus, PubMed, and Google Scholar for studies on neuropsychiatric disorders utilizing conversational data. ResultsFollowing an analysis of 38 selected articles, we highlight verbal episodic memory as a sensitive preclinical AD marker, with supporting evidence from neuroimaging and genetic profiling. Executive functions precede memory decline, while processing speed is a significant correlate. The potential of VR remains underexplored, and AI algorithms offer a multidimensional approach to early neurocognitive disorder diagnosis. ConclusionsEmerging technologies like VR and AI show promise for preclinical diagnostics, but thorough validation and regulation for clinical safety and efficacy are necessary. Continued technological advancements are expected to enhance early detection and management of AD.
ISSN:2291-9694

Similar Items